focus -WSS

focus

author：explore 2025-10-01 04:11:35 - browse：1

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Biotech incubator Curie.Bio graduates its first startup

WSS

More doctors should go into startup world

The Sacklers, horror, and ‘The Fall of the House of Usher’

White House calls on federal agencies to crack down on AI abuses

The Sacklers, horror, and ‘The Fall of the House of Usher’

A clever new way to fix Medicaid and graduate medical education

Abortion clinic in Cancun will cater to Americans

knowledge

focus

focus

Guidelines to prevent youth baseball injuries need more muscle

STAT Summit: Ending the crisis of Black deaths in the U.S.

In Memoriam: Notable people who died in 2023

10 million people disenrolled from Medicaid over past six months

Guidelines to prevent youth baseball injuries need more muscle

White House calls on federal agencies to crack down on AI abuses

Hepatitis C has a cure — but many Americans still lack access to it

MoonLake credibility takes another hit with mid

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: Meghan O’Rourke on making chronic illness visible

leisure time

Questions loom on AstraZeneca cancer drug as safety concerns ebb

ADCs take center stage as promising cancer treatments

J&J lung cancer data amount to new salvo against AstraZeneca

Why a market frenzy over new weight loss drugs defies logic

How AI can help patients find reliable information about doctors

The problems with dementia villages

focus

entertainment

entertainment

leisure time